Xenograft refers to the transplantation of cells, tissues, or organs from one species into a different species. In biotechnology and biomedical research, xenografts are commonly used to model human disease in animal hosts, especially for cancer and immunology studies. Human tumor cells or tissues are implanted into immunodeficient mice to create xenograft models that recapitulate tumor growth, drug response, and metastasis. These models are critical for evaluating therapeutic efficacy, resistance mechanisms, and biomarker discovery. Xenografting provides a controllable in vivo environment that bridges the gap between in vitro assays and clinical studies.
| Xenograft | |
 Xenograft models enable translational research by modeling human disease in animal systems for preclinical evaluation. | |
| Category | In vivo modeling |
| Other names | Heterologous transplant, PDX (patient-derived xenograft) |
| Research fields | Oncology, Immunology, Pharmacology, Regenerative medicine |
| Applications | Cancer modeling, Drug efficacy testing, Immunotherapy evaluation, Tissue engineering |
| Common methods | Subcutaneous injection, Orthotopic implantation, Imaging, Histopathology |
| Related terms | PDX, Humanized mouse, Allograft, Transplantation models |
| Historical development | 1960s–1970s animal cancer modeling, modern PDX in 2000s |
| Sources | |
| Nature Cancer Models; Cancer Cell; Frontiers in Oncology; J. Immunol. Methods | |
History
Xenografting has evolved from basic tumor transplantation into sophisticated models that replicate human disease physiology.
1960s–1970s: Initial Development
Early xenograft studies used immunosuppressed rodents to evaluate tumor biology in vivo. These foundational models enabled correlation between tumor size and therapeutic effect.
1990s–2000s: Patient-Derived Xenografts
Advancements in immunodeficient mouse strains (e.g., NOD/SCID) enabled engraftment of primary human tumors, leading to patient-derived xenograft (PDX) models with higher clinical relevance.
2010s–2020s: Humanized Models and Immunotherapy
Integration of human immune cells into xenograft hosts created platforms for evaluating immunotherapies, checkpoint inhibitors, and personalized treatments in immune-competent settings.
Principles
Xenograft models rely on cross-species transplantation under immunosuppression to support engraftment and in vivo evaluation of human tissues.
Key scientific elements include:
- Host selection: Use of immunodeficient animals (e.g., nude, NSG mice) to prevent rejection
- Engraftment method: Subcutaneous or orthotopic placement of human tissues into host animals
- Tumor growth assessment: Caliper measurements, bioluminescence imaging, and histological analysis
- Drug testing: Systemic or localized delivery of candidate compounds to assess efficacy and toxicity
Methods
Subcutaneous Xenograft
Human tumor cells are injected under the skin of mice to monitor tumor growth and drug response over time.
Orthotopic Xenograft
Tissues are implanted into the corresponding anatomical site (e.g., brain, pancreas) to better mimic tumor microenvironment and metastatic behavior.
Humanized Mouse Xenograft
Xenografts incorporating human immune components (e.g., PBMCs, HSCs) enable immune-oncology studies and evaluation of immunotherapeutics.
Applications
Preclinical Oncology
Xenografts support testing of chemotherapy, targeted agents, and novel biologics in realistic tumor models that mimic clinical behavior.
Biomarker Discovery
Tumor growth kinetics, histology, and molecular profiling in xenografts help identify predictive biomarkers for therapy response or resistance.
Tissue Regeneration and Transplantation
In regenerative medicine, xenograft approaches evaluate human stem cell engraftment, organoid viability, and scaffold compatibility in vivo.
Technology
Instrumentation
In vivo imaging systems (IVIS), digital calipers, cryostats, and pathology platforms support tumor monitoring and post-mortem analysis.
Optimization
Factors like cell number, injection site, matrix support (e.g., Matrigel), and mouse strain are optimized for successful engraftment and study reproducibility.
Study Design
Model Selection
PDX models are stratified by cancer subtype, mutation status, or treatment history. Control groups and randomization enhance validity.
Dosing and Treatment Arms
Therapeutic compounds are administered using standardized routes (oral, IV, IP) and monitored over defined timelines to assess efficacy.
Translational Considerations
Species Limitations
Xenograft models do not fully recapitulate human immune responses or metabolism. Species mismatch can impact pharmacokinetics and drug clearance.
Clinical Relevance
Despite limitations, xenografts inform trial design, dosing strategies, and prioritization of candidates based on in vivo performance in human tissue models.
FAQs
What is the difference between xenograft and allograft?
A xenograft is between species; an allograft is between individuals of the same species.
Are xenograft models immunocompetent?
Standard xenograft models are immunodeficient; humanized models incorporate components of the human immune system.
What are the limitations of xenograft studies?
They may not fully mimic human immune responses, tumor heterogeneity, or drug metabolism.
How are xenografts used in drug development?
They provide in vivo validation of drug efficacy, pharmacodynamics, and resistance mechanisms in human-relevant tumor models.